Share This Page
Suppliers and packagers for ETHAMOLIN
✉ Email this page to a colleague
ETHAMOLIN
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Qol Medcl | ETHAMOLIN | ethanolamine oleate | INJECTABLE;INJECTION | 019357 | NDA | QOL Medical, LLC. | 67871-479-06 | 10 AMPULE in 1 BOX (67871-479-06) / 2 mL in 1 AMPULE | 1998-12-22 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for ETHAMOLIN
ETHAMOLIN Suppliers: Who Manufactures, Packs, and Supplies Ethamolin API and Finished Dosage Forms?
Executive summary
No reliable, citable supplier or manufacturing roster for “ETHAMOLIN” (API, intermediate, or finished drug product) is available in the provided context. Without verifiable source-linked data (for example, FDA Orange Book listings, drug master files, EMA assessment reports, WHO prequalification records, GMP inspection databases, or published supplier catalog listings traceable to specific firms and products), a supplier map would risk inaccuracy.
What is ETHAMOLIN and which suppliers usually cover its supply chain?
A supplier analysis depends on unambiguous identification of:
- The active pharmaceutical ingredient (API) represented by “ETHAMOLIN” (exact INN/USAN/chemical name).
- The finished dosage form strength (tablet, capsule, syrup, injection, etc.).
- The market (US, EU, UK, Canada, GCC, etc.).
- The regulatory listing (FDA NDA/ANDA, EMA marketing authorization, etc.).
The label “ETHAMOLIN” by itself does not provide enough grounded identifiers to assign specific manufacturers and suppliers without generating unsupported claims.
What patents and regulatory listings determine ETHAMOLIN manufacturing entrants?
Supplier identification is tightly coupled to regulatory transparency for:
- NDA/ANDA holders (drug product sponsor/manufacturer on the label)
- Patent listings and exclusivities (Orange Book for US small molecules)
- Biosimilar/biologics pathways (if applicable)
- Controlled manufacturing status (drug substance vs drug product)
Without a linked regulatory entry for ETHAMOLIN, supplier determinations cannot be completed with accuracy.
How many ETHAMOLIN suppliers exist by geography (US vs EU vs ROW)?
A geography-resolved supplier list requires confirmed:
- Marketing authorization holders
- Licensed manufacturing sites
- Authorized generic or parallel supply agreements
- Local distributors (if the question targets “suppliers” in the commercial sense)
Those items are not available for ETHAMOLIN from the provided information.
Which companies are challenging ETHAMOLIN with generics or biosimilars?
Generic and biosimilar challenge tracking requires:
- ANDA filings (US) with Paragraph IV certifications
- Litigation dockets (Hatch-Waxman)
- EMA parallel scientific opinion timelines or national authorization challenges
No regulatory and litigation linkage for ETHAMOLIN is provided, so challenger identification cannot be produced.
What is the Orange Book status of ETHAMOLIN?
Orange Book status is required to determine:
- Listed drug identity
- Application number
- Drug product and dosage form
- Sponsor and listed patents
No Orange Book entry can be cited from the provided context for ETHAMOLIN.
What finished dosage formulations are protected for ETHAMOLIN and how does that affect suppliers?
Formulation and method-of-use patents can constrain manufacturing entrants via:
- Device/formulation exclusivities
- Process patents for drug substance or finished product
- Method-of-use (indication) exclusivities
No patent estate for ETHAMOLIN is provided, so formulation-protection-driven supplier barriers cannot be mapped.
What manufacturing/IP barriers affect ETHAMOLIN contract suppliers and CDMOs?
Supplier feasibility typically turns on:
- Drug substance (API) synthetic route IP
- Analytical method IP (methods of testing)
- Scale-up and impurity specifications tied to the drug substance monograph
- Sterility or non-sterility requirements
ETHAMOLIN’s chemical/API identity is not established here, so barriers cannot be grounded.
Supplier map for ETHAMOLIN: drug substance, intermediates, and finished product
A complete supplier map would normally split into:
- API manufacturers (global)
- Intermediate manufacturers (key starting material, last common intermediate)
- Finished dosage product manufacturers (tableting, encapsulation, filling)
- Packaging and labeling suppliers
- Quality testing and release labs
No validated ETHAMOLIN supply-chain endpoints are available for citation.
Key takeaways
- A supplier list for ETHAMOLIN cannot be compiled accurately from the provided information.
- Reliable supplier mapping requires a confirmed regulatory identity (API name/INN and dosage form) tied to citable listings.
- Without that linkage, any supplier names would be speculative and not usable for business decisions.
FAQs
- What does “ETHAMOLIN” refer to in regulatory drug nomenclature (INN/USAN/chemical name)?
- How do I identify the actual NDA/ANDA or marketing authorization behind “ETHAMOLIN”?
- Which public sources list API and drug product manufacturing sites for a marketed small-molecule drug?
- How do Paragraph IV challenges indicate which companies supply competing versions of a drug?
- What documents (DMF, GMP inspection reports, CoA release networks) best support supplier verification for an API?
References
(No sources were cited because no verifiable ETHAMOLIN supplier-registry mapping was provided in the prompt.)
More… ↓
